{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:59:36Z","timestamp":1772114376294,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.lungcan.2016.01.004","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T12:45:15Z","timestamp":1452516315000},"page":"77-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Medical treatment involving investigational drugs and genetic profile of thymic carcinoma"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9975-2282","authenticated-orcid":false,"given":"Tetsuhiko","family":"Asao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniko","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nokihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-ichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.01.004_bib0005","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.01.004_bib0010","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0015","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/JTO.0b013e3181a4b8e0","article-title":"The management of thymoma: a systematic review and practice guideline","volume":"4","author":"Falkson","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jtcvs.2014.09.124","article-title":"Thymic carcinoma outcomes and prognosis: results of an international analysis","volume":"149","author":"Ahmad","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0025","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0030","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","article-title":"Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma","volume":"6","author":"Agatsuma","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0035","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jjco\/hyr089","article-title":"Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer","volume":"41","author":"Furugen","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0040","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0050","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to Imatinib","volume":"350","author":"Str\u00f6bel","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0060","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0065","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2014.08.020","article-title":"Genetic profiling of thymic carcinoma using targeted next-generation sequencing","volume":"86","author":"Shitara","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.01.004_bib0070","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas","volume":"4","author":"Wang","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/JTO.0000000000000397","article-title":"Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis","volume":"10","author":"Moreira","year":"2015","journal-title":"J. Thorac. Oncol"},{"issue":"10 Suppl. 4","key":"10.1016\/j.lungcan.2016.01.004_bib0080","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","article-title":"Staging system of thymoma","volume":"5","author":"Masaoka","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1634\/theoncologist.2013-0180","article-title":"Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing","volume":"19","author":"Zhang","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2016.01.004_bib0090","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/jjco\/hyl109","article-title":"Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors","volume":"36","author":"Fujisaka","year":"2006","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0095","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00280-007-0530-8","article-title":"Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors","volume":"61","author":"Shimizu","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0100","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00280-009-0979-8","article-title":"Phase I dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors","volume":"64","author":"Yamamoto","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0105","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-09-2425","article-title":"A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies","volume":"16","author":"Kuenen","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0110","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0115","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00280-010-1405-y","article-title":"Phase I pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors","volume":"67","author":"Murakami","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0120","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-10-2638","article-title":"Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors","volume":"17","author":"Yamada","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0125","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00280-012-1846-6","article-title":"An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors","volume":"69","author":"Asahina","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-012-1932-9","article-title":"A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors","volume":"70","author":"Nokihara","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0135","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00280-011-1788-4","article-title":"Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors","volume":"69","author":"Seki","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0140","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1349-7006.2011.02179.x","article-title":"A Phase I dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors","volume":"103","author":"Yamamoto","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2016.01.004_bib0145","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00280-013-2165-2","article-title":"Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors","volume":"71","author":"Yamamoto","year":"2013","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216300058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216300058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T03:55:06Z","timestamp":1537070106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216300058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":29,"alternative-id":["S0169500216300058"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.01.004","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical treatment involving investigational drugs and genetic profile of thymic carcinoma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}